Author: Rachelle Ramirez

Poster-Case Reports / Case Series

Identifying and Treating Steroid-Induced Psychosis in MS Patients Using Quetiapine

Background: High-dose corticosteroids (CS) (1g IV methylprednisolone or 1250 mg oral prednisone for 3-5 days) is the most common treatment...

Read More

Platform-Disease Modifying Therapies

Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-Modifying Drugs: A Systematic Review

Background: It is widely accepted that relapses of multiple sclerosis (MS) decrease during pregnancy; however, studies show an increased...

Read More

Platform-Disease Management

How the COVID-19 Pandemic Has Changed Multiple Sclerosis Clinical Practice: Results of a Nationwide Provider Survey

Background: The COVID-19 crisis has created unanticipated changes in health care delivery for people living with multiple sclerosis (MS)....

Read More

Platform-Psychosocial

The Art of the Patient Conversation: Advanced Practice Provider Perspectives to Improve Outcomes in Multiple Sclerosis

Background: Robust health literacy, defined by the Centers for Disease Control and Prevention as the degree to which an individual can...

Read More

Platform-Psychosocial

Social-Cognitive Correlates of Physical Activity in Fatigued and Non-Fatigued Persons with Multiple Sclerosis

Background: There is interest in the application of behavioral interventions for increasing physical activity among adults with multiple...

Read More

Platform-Rehabilitation

The Effect of Telerehabilitation on the Quality of Life and Fatigue of Patients with Multiple Sclerosis

Background: , Multiple Sclerosis is a chronic neurological disease, characterized by demyelination of neurons in the Central Nervous System...

Read More

Platform-Disease Management

Characterizing Socioeconomic, Lifestyle, and Comorbidity Mediators of Racial Disparities in Ambulatory Impairments in Multiple Sclerosis.

Background: Multiple sclerosis (MS) is more prevalent in White Americans (WAs), yet incidence is now highest in Black Americans (BAs), who...

Read More

Platform-Disease Modifying Therapies

Recently Diagnosed Early-Stage RRMS: Neda, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: Early treatment of multiple sclerosis (MS) and rapid onset of therapeutic effect provide long-term benefits on disease...

Read More

Platform-Neuroimaging

Improving the Utilization of Standardized Mris in Multiple Sclerosis Care: A Pragmatic Trial Perspective

Background: Magnetic resonance imaging (MRI) is a key part of the diagnosis and follow-up of people with multiple sclerosis (MS). However,...

Read More

Platform-Disease Modifying Therapies

Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design

Background: Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of adults with relapsing multiple...

Read More